Innovation in Immunotherapy & Immunomonitoring Platform – PI3

The PI3 platform develops tools to analyze immune parameters in human (blood, tumor environment) and murine tumor models to analyze the deleterious impact of tumors on the immune system and the consequences of innovative immunotherapy strategies.

I- In the context of clinical trials, PI3 performs longitudinal immune monitoring studies on human blood to identify predictive factors of response and define mechanisms of primary or acquired resistance in order to discover new immunotherapy targets.

II- PI3 is developing multi-IF staining tools to assess the in situ immune contexture in human tumors (in collaboration with the bio-pathology platforms)

III- PI3 is developing immunophenotyping tools in syngeneic murine tumor models to evaluate new immuno-therapeutics and measure the anti tumor immune response (in collaboration with the LMT platform).

The PI3 platform provides expertise in human and mouse immune responses to tumors with a particular focus on innate and adaptive immune cells at the phenotypic and functional levels both in the periphery and in situ at the tumor site.

Based on highly competent personnel, we develop :

Customized flow cytometry panels to investigate in human and murine models i) the expression of targets of interest on immune cells, ii) the functional competence of immune cells of interest, iii) the tumor Ag-specific response and iv) the impact of new immuno-modulators in preclinical studies.

Multi IF staining to assess the in situ localization, structuration and activation status of immune cells, and target expression before and after immunotherapy.

EXPERTISE

Development of flow cytometry tools to quantify and functionality assess innate and adaptive cell subsets
Analysis of Ag specific responses
Quantification of soluble parameters
Development of multi-parametric IF staining to characterize immune context in situ
Development of cytometry tools to characterize immune cells, activation status and functionality in syngeneic immunotherapy murine tumor models

APPLICATIONS

Longitudinal immuno-monitoring of clinical trials.
Evaluation of efficacy compounds targeting innate or adaptive immune functions.
Evaluation of blood immune cell activation or inhibition status.
Immune cell competency in blood.
Quantification of secretome.
Detection by in situ multi-IF of the localization, structure and activation status of immune cells within the tumor environment in clinical trials and pre-clinical models.
In vivo, evaluation of new therapeutic strategies or immunotherapy drug candidates on tumor control and tumor immune response in pre-clinical models.

INSTRUMENTATION

FACS CANTO-II (BD)
Access to LSR-II Fortessa (BD)
Luminex (BIORAD)
ELISA (Multiskan FC)
FLUOROSPOT (CTL)
DIVA (BD)
FlowJo (TreeStar)
GraphPad Prism

TYPE OF SERVICE

Clinical trial immuno-monitoring
Translational projects
Pre-clinical projects
Development of in situ evaluation of immune cell interactions in tumors (collaboration with pathology platforms)
Immune cell characterization in syngeneic murine tumor models (collaboration with LMT)
There is no free access to platform equipment.

MENTION US IN YOUR PUBLICATIONS

Together we will define if collaborative studies require co-authorship or acknowledgement as follows:
Plateforme d’innovation en immunomonitoring et immunothérapie (PI3), Département de recherche translationnelle et d’innovations, Centre Léon Bérard, Lyon France.
We thank the (specific coordinator name) for his/her contribution to i) clinical trial immuno-monitoring, ii) immune contexture analysis or iii) immunotherapy preclinical murine models.